GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Cyclically Adjusted FCF per Share

PMCB (PharmaCyte Biotech) Cyclically Adjusted FCF per Share : $-4.52 (As of Jan. 2025)


View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

PharmaCyte Biotech's adjusted free cash flow per share for the three months ended in Jan. 2025 was $-0.073. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-4.52 for the trailing ten years ended in Jan. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -1.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -2.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of PharmaCyte Biotech was 17.40% per year. The lowest was -5.40% per year. And the median was 4.70% per year.

As of today (2025-07-01), PharmaCyte Biotech's current stock price is $1.14. PharmaCyte Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2025 was $-4.52. PharmaCyte Biotech's Cyclically Adjusted Price-to-FCF of today is .


PharmaCyte Biotech Cyclically Adjusted FCF per Share Historical Data

The historical data trend for PharmaCyte Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech Cyclically Adjusted FCF per Share Chart

PharmaCyte Biotech Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.86 -5.18 -5.57 -5.69 -5.42

PharmaCyte Biotech Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.59 -5.42 -5.22 -4.79 -4.52

Competitive Comparison of PharmaCyte Biotech's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, PharmaCyte Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Cyclically Adjusted Price-to-FCF falls into.


;
;

PharmaCyte Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmaCyte Biotech's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=-0.073/134.0288*134.0288
=-0.073

Current CPI (Jan. 2025) = 134.0288.

PharmaCyte Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201504 -2.307 99.824 -3.098
201507 -2.163 100.691 -2.879
201510 -2.119 100.346 -2.830
201601 -2.002 99.957 -2.684
201604 -2.376 100.947 -3.155
201607 -1.724 101.524 -2.276
201610 -1.247 101.988 -1.639
201701 -1.614 102.456 -2.111
201704 -1.358 103.167 -1.764
201707 -1.517 103.278 -1.969
201710 -2.459 104.070 -3.167
201801 -1.802 104.578 -2.309
201804 -2.061 105.708 -2.613
201807 -0.891 106.324 -1.123
201810 -1.273 106.695 -1.599
201901 -0.899 106.200 -1.135
201904 -0.863 107.818 -1.073
201907 -0.945 108.250 -1.170
201910 -0.661 108.577 -0.816
202001 -0.384 108.841 -0.473
202004 -0.611 108.173 -0.757
202007 -0.492 109.318 -0.603
202010 -0.812 109.861 -0.991
202101 -0.378 110.364 -0.459
202104 -0.596 112.673 -0.709
202107 -0.780 115.183 -0.908
202110 -0.080 116.696 -0.092
202201 -0.014 118.619 -0.016
202204 -0.056 121.978 -0.062
202207 -0.052 125.002 -0.056
202210 -0.091 125.734 -0.097
202301 -0.029 126.223 -0.031
202304 -0.016 127.992 -0.017
202307 0.027 128.974 0.028
202310 -0.226 129.810 -0.233
202401 -0.021 130.124 -0.022
202404 -0.040 132.289 -0.041
202407 -0.047 132.708 -0.047
202410 -0.138 133.182 -0.139
202501 -0.073 134.029 -0.073

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


PharmaCyte Biotech  (NAS:PMCB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


PharmaCyte Biotech Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaCyte Biotech Business Description

Industry
Traded in Other Exchanges
N/A
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb director 100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen director 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K director
Carlos Trujillo director, officer: CFO 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner director, officer: Chairman, CEO, Pres and GC 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree director, officer: Chief Science Officer 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099